Breaking Down Hunan Er-Kang Pharmaceutical Co., Ltd Financial Health: Key Insights for Investors

Peeling back the numbers on Hunan Er-Kang Pharmaceutical (300267.SZ) reveals a company of contrasts: first-half 2025 revenue rose to CN¥681.88 million (a 10% increase year‑on‑year), yet full‑year sales plunged from CN¥1.78 billion in 2023 to CN¥1.14 billion in 2024 (≈36% decline) driven by a 33.28% fall in domestic and a 51.01% fall in overseas sales; profitability metrics show a net loss of CN¥373.37 million in 2024 (up 91.2% vs. 2023), ROE at -8.02%, EPS -CN¥0.15 and operating income of -CN¥63.56 million, while margins contracted (gross margin ~24.6%, net margin -28.9%); the balance sheet paints a mixed picture with total debt of CN¥422.04 million, cash of CN¥706.06 million and a net cash position of CN¥284.02 million, low leverage (debt/equity 0.10), healthy liquidity (current ratio 2.71, quick ratio 1.50) but a negative interest coverage of -8.31; valuation signals tension-market cap rose to CN¥6.97 billion as of Oct 3, 2025 (+21.58% vs end-2024), EV/EBITDA stands at 59.89, EV/FCF at -363.52 and EV/sales at 6.49, even as the stock is up 65.56% over 52 weeks with a low beta of 0.25; operational flags include declining revenue per employee (CN¥837,833 in 2024 from CN¥889,020 in 2023) alongside headcount falling from 1,497 to 1,453, a CNY 10 million fine for unfair pricing on Chlorpheniramine API, and rising debt over five years-read on to parse how liquidity strengths, valuation extremes, regulatory risks and early‑2025 topline recovery shape investor choices

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Revenue Analysis

Key revenue movements and efficiency metrics for Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) across 2023-2025, highlighting the sharp annual revenue contraction in 2024 and partial recovery in H1 2025.

• Revenue (annual): CN¥1.78 billion (2023) → CN¥1.14 billion (2024), a decline of ~36%.
• H1 revenue: CN¥621.35 million (H1 2024) → CN¥681.88 million (H1 2025), a 10% year‑over‑year increase.
• Primary drivers of 2024 decline: domestic sales down 33.28% and overseas sales down 51.01% vs. 2023.
• Workforce and productivity: employees decreased from 1,497 (2023) to 1,453 (2024); revenue per employee fell from CN¥889,020 (2023) to CN¥837,833 (2024).
• Market capitalization: CN¥5.73 billion at end‑2024 → CN¥6.97 billion on 3 Oct 2025 (+21.58%).

• Interpretation pointers:
  • The 36% annual revenue drop in 2024 was driven by large contractions in both domestic and international channels.
  • H1 2025 recovery (+10% YoY) indicates partial stabilization but remains below 2023 full‑year levels.
  • Revenue per employee decline signals reduced workforce productivity or changes in product mix/pricing.
  • Market cap rebound to CN¥6.97 billion by Oct‑3‑2025 suggests investor sentiment improved despite lingering revenue weakness.

Further investor context: Exploring Hunan Er-Kang Pharmaceutical Co., Ltd Investor Profile: Who's Buying and Why?

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Profitability Metrics

• Net loss (2024): CN¥373.37 million, a 91.2% increase from CN¥195.3 million in 2023.
• Return on equity (ROE, 2024): -8.02%, indicating negative returns to shareholders.
• Earnings per share (TTM): -CN¥0.15, signaling ongoing unprofitability.
• Operating income (TTM): -CN¥63.56 million, reflecting operational challenges and negative core results.
• Gross profit margin (2024): ~24.6%, down from 28.3% in 2023 - higher COGS pressure.
• Net profit margin (2024): -28.9%, showing the company incurred losses on sales after all expenses.

• Implications for investors: deteriorating margins and amplified net losses signal increased earnings risk and potential pressure on equity value unless earnings turnaround or cost structure improvements occur.
• Operational focus areas: gross margin decline points to cost of goods sold and pricing; negative operating income suggests need for operational efficiencies or portfolio/product adjustments.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio (2024): 0.10 - low financial leverage on a simple balance-sheet ratio basis.
• Total debt (2024): CN¥422.04 million; Cash & cash equivalents: CN¥706.06 million - net cash position of CN¥284.02 million.
• Interest coverage ratio (2024): -8.31 - operating income insufficient to cover interest expense, signaling operating losses or negative EBIT.
• Equity-to-assets ratio: reduced due to accumulated losses, weakening the equity base despite low headline leverage.
• Five-year trend: rising debt levels contributing to negative return on equity and heightened financial risk.
• Regulatory headwinds: recent regulatory challenges amplify the need to examine maturity profile, covenants, and contingent liabilities.

• Cash burn and trajectory to profitability - given negative interest coverage.
• Debt maturity schedule and any near-term refinancing needs or covenant triggers.
• Potential regulatory-related contingent liabilities that could strain capital ratios.
• Movement in equity base (retained earnings) and any capital raises that could dilute shareholders.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Liquidity and Solvency

• Current ratio: 2.71 (2024) - indicates sufficient short-term assets to cover short-term liabilities.
• Quick ratio: 1.50 (2024) - shows the company can meet short-term obligations without relying on inventory.
• Net cash position: CN¥284.02 million - cash reserves exceed total debt, providing a liquidity cushion.
• Short-term assets comfortably cover both short- and long-term liabilities - supporting solvency.
• Overall liquidity and solvency remain strong despite profitability challenges.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Valuation Analysis

This chapter breaks down market and valuation metrics for Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) and highlights implications for different investor types based on current market pricing and cash-flow dynamics.

• Market capitalization: CN¥6.97 billion (as of October 3, 2025), up 21.58% from CN¥5.73 billion at end-2024.
• 52-week price performance: +65.56%, signaling strong price momentum and positive sentiment over the past year.
• Beta: 0.25 - substantially lower volatility than the market, suggesting defensiveness or low correlation with broader market moves.

Key valuation takeaways and considerations for investors:

• High EV/EBITDA (59.89) and EV/Sales (6.49) indicate the market is pricing in substantial future profitability or growth; current operating earnings do not justify the multiple on a historical or conservative basis.
• EV/FCF of -363.52 is a red flag for cash-focused investors - negative free cash flow can constrain shareholder returns (dividends, buybacks) and increases dependency on external financing to fund operations or growth.
• The sharp 52-week gain (+65.56%) combined with a low beta (0.25) suggests recent positive company- or sector-specific developments were priced in without commensurate market-wide volatility - monitor whether price moves reflect durable fundamentals or short-term sentiment.
• Given the elevated valuation metrics, upside for growth-oriented investors depends on the company delivering materially higher EBITDA margins, accelerating revenue growth, or restoring positive free cash flow.
• Value-oriented or income-seeking investors should be cautious until FCF normalizes or valuation multiples compress to more historically typical levels for the sector.

For context on corporate strategy and long-term direction that could justify these valuation levels, see: Mission Statement, Vision, & Core Values (2026) of Hunan Er-Kang Pharmaceutical Co., Ltd.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Risk Factors

• CNY 10 million regulatory fine from the State Administration for Market Regulation for unfair pricing practices involving Chlorpheniramine API.
• Sharp revenue contraction: annual revenue fell from CN¥1.78 billion in 2023 to CN¥1.14 billion in 2024 (-35.96%).
• Large and growing net losses: net loss of CN¥373.37 million in 2024, a 91.2% increase versus the prior year loss.
• Negative return on equity: ROE at -8.02% in 2024, reflecting sustained unprofitability and capital erosion.
• Rising leverage: debt levels have increased over the past five years, amplifying financial risk and contributing to negative ROE.
• Weak interest coverage: interest coverage ratio of -8.31 in 2024, indicating operating losses insufficient to cover interest expense.

• Operational risks: revenue decline suggests product demand weakness, pricing pressure, or loss of market share in key APIs and formulations.
• Regulatory & compliance risk: the CNY 10 million fine underscores vulnerability to administrative penalties and reputational damage that can affect tender access and pricing.
• Liquidity risk: mounting losses and negative interest coverage raise short-term liquidity concerns, potentially necessitating asset disposals, equity raises, or refinancing at higher cost.
• Leverage and refinancing risk: rising debt over five years increases sensitivity to interest-rate moves and covenant breaches, exacerbated by negative operating cash flow.
• Investor dilution risk: potential capital injections to shore up balance sheet could dilute existing shareholders if new equity is issued.
• Credit risk: suppliers and lenders may demand stricter terms or higher spreads, increasing cost of capital and reducing margin recovery prospects.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Growth Opportunities

Hunan Er-Kang Pharmaceutical's recent performance and structural strengths point to multiple avenues for expansion across product lines, geographies, and capital deployment.

• Revenue momentum: reported a 10% increase in revenue in H1 2025 vs H1 2024, signalling demand traction.
• Positive market sentiment: market capitalization rose by 21.58% in 2025, reflecting investor confidence.
• Diversified product portfolio: includes APIs, finished drug products, and pharmaceutical excipients, enabling cross-segment growth.
• Experienced leadership: management team average tenure of 5.5 years, supporting execution of strategic initiatives.
• Financial flexibility: cash reserves exceed total debt, providing capacity for M&A, R&D investment, or capacity expansion.
• International expansion: overseas sales of CN¥138.62 million in 2024, offering a platform for further global penetration.

Key tactical areas where these strengths can convert into measurable growth include expanding export channels for APIs and finished drugs, prioritizing high-margin finished products, targeted M&A financed from strong liquidity, and leveraging experienced management to accelerate commercialization. For context on the company's strategic framing, see: Mission Statement, Vision, & Core Values (2026) of Hunan Er-Kang Pharmaceutical Co., Ltd.